Akari Therapeutics Stock Falls After 255 Percent Weekly Gain
Akari Therapeutics PLC shares declined on Tuesday following a 255 percent surge late last week. The movement came after the company reported preclinical results for its AKTX-101 asset in KRAS-mutated pancreatic cancer models.
manilatimes.netAkari Therapeutics PLC (NASDAQ: AKTX) stock declined Tuesday after rising 255 percent in the prior session. The pullback followed the release of preclinical laboratory data on the company's asset AKTX-101.
The data showed that AKTX-101 produced synergistic cell-killing activity when combined with the KRAS inhibitor adagrasib. The effect appeared in cell lines carrying KRAS G12D and KRAS G12C mutations. The same synergy was not observed when adagrasib was tested with first-in-class TROP2 antibody-drug conjugates that use traditional topoisomerase I inhibitor payloads.
Those combinations instead showed antagonistic effects. The company presented the contrast between the two payload types in its report on the findings.
Key Facts
Story Timeline
2 events- Friday
Akari stock rose after release of preclinical data on AKTX-101.
1 sourceBenzinga - Tuesday
Akari shares declined following the prior 255 percent gain.
1 sourceBenzinga
Potential Impact
- 01
Share price volatility may continue as investors assess the preclinical findings.
- 02
Further laboratory or animal studies could be required before clinical testing.
Transparency Panel
Related Stories
al-monitor.comIran Says Strait of Hormuz Management Belongs to Iran and Oman
Iran's Foreign Ministry spokesperson stated that control of the Strait of Hormuz must be decided solely by Iran and Oman. The spokesperson also said no agreement has been reached with the United States and that current focus remains on ending the war.
Financial TimesRomania Expels Russian Consul General After Drone Strike
Romania ordered the expulsion of Russia's Consul General in Constanta and closed the consulate after a drone struck an apartment building in Galati, injuring two people. NATO and Romanian officials condemned the incident as reckless escalation.
fortune.comHouse Republicans stall on immigration enforcement funding bill
A roughly $70 billion measure to fund immigration enforcement through the end of President Donald Trump's term stalled in the House. Progress halted over White House ballroom security funding and a proposed $1.8 billion fund for government-mistreatment claims.